What is it about?
LIQ861 is an inhaled form of treprostinil. This study examines the safety of LIQ861 in patients with pulmonary arterial hypertension. We will also assess the impact of LIQ861 on the hemodynamics of the lungs.
Featured Image
Why is it important?
This study will establish the safety as well as the short- and long-term hemodynamic effects of LIQ861 in patients with pulmonary arterial hypertension.
Perspectives
This is an important study that adds to the clinical research program for LIQ861 and helps us understand the role of LIQ861 in the treatment of pulmonary arterial hypertension.
Robert Roscigno
Liquidia Technologies Inc
Read the Original
This page is a summary of: LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients, September 2020, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2020.1459.
You can read the full text:
Contributors
The following have contributed to this page
